Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dutasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 known ✓ | P18405 | 19/20 | 1.00 |
| ▸ | SRD5A2 known ✓ | P31213 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 1/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dutasteride SCHEMBL1832772 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1285958 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL9975973 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL5903 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1108295 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL13495828 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL997007 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL12194984 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL20776136 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL4775587 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414378-B1 | SEPARATION OF 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF SA (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8664395-B2 | Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid | PHF S.A. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8435975-B2 | Steroidal esters of 17-oximino-5-androsten-3beta-ol | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-05-07 | — | — | US | disclosed |
| US-20120029196-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20100292201-A1 | NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3BETA-OL | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100292201-A1 | NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3BETA-OL | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2010112079-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292201-A1 | NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3BETA-OL | CYP17A1, HSD17B7, SRD5A2 | SRD5A1 4/4885SRD5A2 3/4885LMNA 3768/4885 |
| US-20120029196-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | NR5A1, SRD5A2, CYP19A1 | SRD5A1 4/4885SRD5A2 2/4885LMNA 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.